EU grants Adempas label expansion

|By:, SA News Editor

The European Commission approves Bayer's (BAYRY) Adempas (riociguat) for two serious types of pulmonary hypertension: chronic -thromboembolic pulmonary hypertension ((CTEPH)) and pulmonary arterial hypertension ((PAH)).

The FDA approved the same indications in October.

The company forecasts peak sales of ~$700M.